**HIV POST-EXPOSURE PROPHYLAXIS (PEP) TREATMENT**

*The human immunodeficiency virus (HIV) post-exposure prophylaxis (PEP) starter kits are provided by the Saskatchewan Ministry of Health. These starter kits are located in a variety of health care facilities throughout Saskatchewan. The starter kits contain tenofovir disoproxil fumarate/emtricitabine (Truvada or listed generic) and raltegravir (Isentress) for 5 days of treatment. The remaining course of HIV PEP medications can be obtained with a prescription upon consultation with an Infectious Disease (ID) specialist. The ID specialist will provide recommendations on the appropriate HIV PEP regimen. The Saskatchewan Guidelines for the Management of Exposures to Blood and Body Fluids are currently under revision to reflect this change. New versions will be posted on the following link: [https://www.ehealthsask.ca/services/Manuals/Pages/hiv-guidelines.aspx](https://www.ehealthsask.ca/services/Manuals/Pages/hiv-guidelines.aspx) when the updates are finalized.*

**REMEMBER:** The remaining course of HIV PEP medications will be provided to the client free of charge for Drug Plan beneficiaries when exposure is *not* the result of a workplace injury covered under Worker’s Compensation Board (WCB).

To receive approval for the coverage of any Exception Drug Status (EDS) medications included in the HIV PEP treatment regimen, pharmacies will submit a prescription claim through the Drug Plan network for Drug Plan beneficiaries.

- a) If the prescriber is an ID specialist, Exception Drug Status (EDS) is automatically approved through online EDS adjudication (OEA).
- b) If the prescriber is not an ID specialist, the pharmacist calls the Drug Plan for approval and will indicate “HIV PEP medication in consultation with ID specialist”. The Drug Plan will approve the EDS coverage.

Pharmacies can then submit the remainder of the HIV PEP prescription claim (i.e., up to 23 days’ supply of the PEP medication) to the Drug Plan for coverage at no cost to the patient.

The Drug Plan authorizes Exception Drug Status (EDS) for the following drugs as noted below for HIV post-exposure prophylaxis (PEP):

**Regimen 1:** emtricitabine/tenofovir disoproxil fumarate, tablet, 200mg/300mg (Truvada-GSI and listed generics)\(^1\) and raltegravir, tablet, 400mg (Isentress-MSD)

When prescribed by, or on the advice of an Infectious Disease specialist familiar with HIV treatment, for post-exposure prophylaxis (PEP).
The following are alternatives to complete 28 days HIV PEP in special circumstances:

**Regimen 2:** darunavir, tablet, 800mg (Prezista-JAN), ritonavir, tablet, 100mg (Norvir-ABB) and emtricitabine/tenofovir disoproxil fumarate, tablet, 200mg/300mg (Truvada-GSI and listed generics)¹
When prescribed by, or on the advice of an Infectious Disease specialist familiar with HIV treatment, for post-exposure prophylaxis (PEP).

**Regimen 3:** dolutegravir, tablet, 50mg (Tivicay-VII) and emtricitabine/tenofovir disoproxil fumarate, tablet, 200mg/300mg (Truvada-GSI and listed generics)¹
When prescribed by, or on the advice of an Infectious Disease specialist familiar with HIV treatment, for post-exposure prophylaxis (PEP).

**Regimen 4:** lamivudine/zidovudine, tablet, 150mg/300mg (Combivir-VII) and lopinavir/ritonavir, tablet, 200mg/50mg (Kaletra-ABB)
When prescribed by, or on the advice of an Infectious Disease specialist familiar with HIV treatment, for post-exposure prophylaxis (PEP).

¹ emtricitabine/tenofovir disoproxil fumarate is a full Formulary benefit and would not require EDS approval.